Atara Biotherapeutics (ATRA) Accumulated Expenses (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Accumulated Expenses came in at $1.8 million in Q1 2026, down 61.86% YoY from $4.6 million in Q1 2025, and down 2.45% on a QoQ basis from $1.8 million in Q4 2025.
Atara Biotherapeutics (ATRA) Accumulated Expenses (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Accumulated Expenses data on file, last reported at $1.8 million in Q1 2026.
- Quarterly Accumulated Expenses fell 61.86% year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (down 61.86% YoY) and the FY2025 annual result came in at $1.8 million, down 70.17% from the prior year.
- Accumulated Expenses eased to $1.8 million in Q1 2026, from $1.8 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $19.0 million in Q4 2023 to a low of $349000.0 in Q1 2023.
- A 5-year average of $8.4 million and a median of $7.3 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2023 — Accumulated Expenses tumbled 97.87% — and 2024, when it surged 5115.76%.
- Tracing ATRA's Accumulated Expenses over 5 years: stood at $7.4 million in 2022, then soared by 155.64% to $19.0 million in 2023, then plunged by 68.29% to $6.0 million in 2024, then slumped by 70.17% to $1.8 million in 2025, then declined by 2.45% to $1.8 million in 2026.
- The last three Accumulated Expenses figures came in at $1.8 million (Q1 2026), $1.8 million (Q4 2025), and $2.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Atara Biotherapeutics | 141.08 Mn | 124.53 Mn | 439,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.16 Mn |
| Mar 31, 2026 | 1.75 Mn |
| Dec 31, 2025 | 1.80 Mn |
| Sep 30, 2025 | 2.55 Mn |
| Jun 30, 2025 | 4.78 Mn |
| Mar 31, 2025 | 4.60 Mn |
| Dec 31, 2024 | 6.03 Mn |
| Sep 30, 2024 | 7.77 Mn |
| Jun 30, 2024 | 7.27 Mn |
| Mar 31, 2024 | 18.20 Mn |
| Dec 31, 2023 | 19.01 Mn |
| Sep 30, 2023 | 763,000.00 |
| Jun 30, 2023 | 10.65 Mn |
| Mar 31, 2023 | 349,000.00 |
| Dec 31, 2022 | 7.44 Mn |
| Sep 30, 2022 | 17.61 Mn |
| Jun 30, 2022 | 16.32 Mn |
| Mar 31, 2022 | 16.38 Mn |
| Dec 31, 2021 | 5.96 Mn |
| Sep 30, 2021 | 19.14 Mn |